Concepedia

Author

David Urech

University of GenevaORCID

Also Known As

D M Urech, David M. Urech, David Urech, Urech, David M.

29

Publications

529

Citations

11

H-Index

25

Concepts

All Affiliations

University of GenevaUniversity of LausanneAgile Therapeutics (United States)
DU

About

David Urech is an author at University of Geneva specializing in medicine, cell signaling, and cytoskeleton.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

97

2

Cell Biology

2

2

49

3

Cellular Physiology

2

2

49

4

Biochemistry

1

1

17

5

Biomedical Engineering

1

1

11

David Urech

×

12

Publications

424

Citations

11

H-Index

YearCitations

Relative Contribution of VEGF and TNF-α in the Cynomolgus Laser-Induced CNV Model: Comparing the Efficacy of Bevacizumab, Adalimumab, and ESBA105

Peter Lichtlen, Tim T. Lam, T. Michael Nork,

Investigative Ophthalmology & Visual Science

2010

71

Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use

David Urech, Ulrich Feige, Stefan Ewert,

Annals of the Rheumatic Diseases

2009

64

Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal Antibodies

Leo Borras, Tea Gunde, Julia Tietz,

Journal of Biological Chemistry

2010

63

Pharmacokinetics and Posterior Segment Biodistribution of ESBA105, an Anti–TNF-α Single-Chain Antibody, upon Topical Administration to the Rabbit Eye

Esther Furrer, Marianne Berdugo, Cinzia Stella,

Investigative Ophthalmology & Visual Science

2009

57

Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain

Esther Furrer, Valérie Hulmann, David Urech

Journal of Neuroimmunology

2009

37

Cell growth selection system to detect extracellular and transmembrane protein interactions

David Urech, Peter Lichtlen, Alcide Barberis

Biochimica et Biophysica Acta (BBA) - General Subjects

2003

32

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

Stefan Warmuth, Tea Gunde, Daniel Snell,

OncoImmunology

2021

32

Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments

Timothy J. Egan, Dania Diem, Richard Weldon,

mAbs

2016

19

Effects of N-glycosylation of the human cation channel TRPA1 on agonist-sensitivity

Timothy J. Egan, Mario A. Acuña, Marcy Zenobi‐Wong,

Bioscience Reports

2016

17

Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment

Lutz R. Asmus, John P.A. Grimshaw, Philipp Richle,

European Journal of Pharmaceutics and Biopharmaceutics

2015

11

Page 1